IRAK4-IN-6 是一种选择性的、口服有效的IRAK抑制剂，IC50为 4 nM，靶向 MyD88 L265P 突变型弥漫性大 B 细胞淋巴瘤。

IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC 50 of 4 nM. IRAK4-IN-6 targetes MyD88 L265P mutant diffuse large B cell lymphoma [1].

2454244-02-9

C25H32N10O2

504.59

IRAK4-IN-6

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years